Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Gains from Sales and Divestitures (2022 - 2024)

Lucid Diagnostics (LUCD) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $26912.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Gains from Sales and Divestitures fell 91.15% year-over-year to $26912.0, compared with a TTM value of $26912.0 through Dec 2024, down 91.15%, and an annual FY2024 reading of $26912.0, down 91.15% over the prior year.
  • Gains from Sales and Divestitures was $26912.0 for Q4 2024 at Lucid Diagnostics, roughly flat from $26912.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $303980.0 in Q3 2023 and bottomed at $26912.0 in Q1 2024.
  • Average Gains from Sales and Divestitures over 3 years is $132356.8, with a median of $109660.0 recorded in 2022.
  • The sharpest move saw Gains from Sales and Divestitures surged 79.53% in 2023, then plummeted 91.15% in 2024.
  • Year by year, Gains from Sales and Divestitures stood at $169320.0 in 2022, then soared by 79.53% to $303980.0 in 2023, then tumbled by 91.15% to $26912.0 in 2024.
  • Business Quant data shows Gains from Sales and Divestitures for LUCD at $26912.0 in Q4 2024, $26912.0 in Q3 2024, and $26912.0 in Q2 2024.